Global Hydatidiform Mole Market, Drug Type (Branded and Generics), Treatment Type (Surgery, Chemotherapy, Radiation Therapy), End User (Hospitals, Specialty Clinics, Diagnostic Centers and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2029
Hydatidiform Mole Market Analysis and Size
The global hydatidiform mole market is expected to witness significant growth during the forecast period. Increased risk factors affecting this disease arena is expected to drive market growth. These risk factors include the rise in ectopic pregnancies, high maternal age and excessive smoking. Difficulty in diagnosing the types of hydatidiform moles may hamper the market growth. The incidence is seen to be high in developing countries and is more common in women younger than 20 years.
Data Bridge Market Research analyses a growth rate in the global hydatidiform mole market in the forecast period 2022-2029. The expected CAGR of global hydatidiform mole market is tend to a healthy CAGR in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
A molar pregnancy often referred to as a hydatidiform mole, is an uncommon pregnancy problem marked by aberrant trophoblast development, which are the cells that typically develop into the placenta. A molar pregnancy may initially appear to be a typical pregnancy, but most of these pregnancies induce particular signs and symptoms, such as: First trimester vaginal bleeding ranges from dark brown to bright red.
Hydatidiform Mole Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Type (Branded and Generics), Treatment Type (Surgery, Chemotherapy, Radiation Therapy), End User (Hospitals, Specialty Clinics, Diagnostic Centers and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Hikma Pharmaceuticals PLC (U.K.), Pfizer Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Antares Pharma (U.S.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Isreal), BP Pharma (Ireland), Accord Healthcare, Inc. (U.S.), Eli Lilly and Company (U.S.), Sanofi (France), Bayer AG (Germany), Amgen Inc (U.S.)
|
|
Market Opportunities
|
|
Global Hydatidiform Mole Market Dynamics
Drivers
- Increase in Smoking
The rising number in smoking could lead to the increase in the diseased condition. According to the American Lung Association (ALA), cigarette smoking kills an estimated 201,770 women annually in the U.S. Thus, it acts as a major driver in the market growth.
- Patient Preference for Non-invasive Procedures
The demand for minimally invasive procedures has considerably expanded in recent years due to the advantages these techniques offer over traditional treatment methods. The benefits of minimally invasive therapies include fewer operating complications, a shorter hospital stay, less discomfort, smaller and more cosmetic incisions, a lower risk of infection, less post-operative care, and a quicker recovery. Modern methods are employed in minimally invasive procedures to diagnose and treat a range of illnesses, including cancer.
Opportunities
- Emerging Economies in the Oncology Sector
It is anticipated that accelerating economic growth and rising healthcare costs will make access to high-quality healthcare easier in many developing countries, including Brazil, Mexico, and India. This is seen as a good indicator for the expansion of interventional oncology. Different interventional oncology products and therapies are becoming more necessary as the incidence of cancer rises in these countries.
- Increasing Demand for Chemotherapy
Anti-cancer medications are administered orally or by injection as part of chemotherapy treatment. This treatment is effective for tumours that have progressed to distant organs since these medications penetrate the bloodstream and reach every part of the body (metastasized). Patients with molar pregnancy are shifting towards this treatment set, thus creating an opportunity for market growth.
Restraints/Challenges
- High Cost
The huge expenditure required for the surgeries and treatment processes surely hamper the market growth. Several market players make huge investment in installing new and advanced treatment procedures to faster the recovery process and in return the cost is increased.
This global hydatidiform mole market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global hydatidiform mole market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Hydatidiform Mole Market
Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business. Its long-term repercussions are expected to influence industry growth during the forecast period.
In the post-pandemic era, COVID-19 is expected had a negative impact on the market initially as all the clinical trials and elective surgeries were postponed. But in the post pandemic era, the market is slowly getting boosted as the surgeries and patient visits increase.
Global Hydatidiform Mole Market Scope
The global hydatidiform mole market is segmented on the basis of drug type, treatment type, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Type
- Branded
- Generics
Treatment Type
- Surgery
- Chemotherapy
- Radiation Therapy
End User
- Hospitals
- Specialty Clinics
- Diagnostic Centers
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Hydatidiform Mole Market Regional Analysis/Insights
The global hydatidiform mole market is analysed and market size insights and trends are provided by drug type, treatment type, distribution channel and end-user as referenced above.
The major countries covered in the global hydatidiform mole market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
America is dominating the market in the forecast period due to the large number of healthcare services and demand of products for huge storage and repository.
Asia-Pacific is considered the most lucrative period due to the region's increasing number of biobanks and hospitals.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Hydatidiform Mole Market Share Analysis
The global hydatidiform mole market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global hydatidiform mole market
Key players operating in the global hydatidiform mole market include:
- Hikma Pharmaceuticals PLC (U.K.)
- Pfizer Inc. (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Antares Pharma (U.S.)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Isreal)
- BP Pharma (Ireland)
- Accord Healthcare, Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- Sanofi (France)
- Bayer AG (Germany)
- Amgen Inc (U.S.)
SKU-